Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar seanyt72 (< 20) Submitted: 10/25/2011 8:56:37 PM : Outperform Start Price: $8.37 HALO Score: -6.95

Breast cancer drug will pass all clinical trials and send this stock through the roof...

Featured Broker Partners


Advertisement